Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate side effects after sublingual misoprostol (600 mcg) as a first-line
treatment for primary postpartum hemorrhage (PPH) due to suspected uterine atony.
Phase:
N/A
Details
Lead Sponsor:
Gynuity Health Projects
Collaborators:
Bill and Melinda Gates Foundation University of Liverpool